Search This Blog

Friday, April 23, 2021

California goes from worst to first in virus infections

 Just a few months ago, California was the epicenter of the coronavirus pandemic in the U.S. Hospitals in Los Angeles were drowning in patients, and ambulances were idling outside with people struggling to breathe, waiting for beds to open.

The death count was staggering — so many that morgues filled and refrigerated trucks were brought in to handle the overflow.

Now as cases spike in other parts of the country, California has gone from worst to first with the lowest infection rate in the U.S. even as it has moved quickly to reopen more businesses with greater customer counts and allow larger gatherings.

A scramble to get COVID-19 vaccinations has given way to an open invite in many places. Where people lined up hours and counties struggled to get doses, there now appears to be a glut of the shots in many locations.

“It has been a success story for California to have gone from our, if you will, viral tsunami that happened after the back-to-back holiday season to where we are now,” said Dr. Robert Kim-Farley of the University of California, Los Angeles’ public health school.

At the peak of California’s winter surge that followed the Thanksgiving, Christmas and New Year’s holidays, the state was recording 40,000 new cases daily and well above 500 deaths per day. Those numbers have dwindled to 2,300 new cases and 68 deaths daily.

The state surpassed Hawaii on Thursday with the lowest average number of cases per capita in the past two weeks, according to data compiled by Johns Hopkins University. One in every 2,416 people in California tested positive in the past week. At the other end of the spectrum, one in every 223 people in Michigan was diagnosed with the virus.

Kim-Farley said it’s been like turning around a massive tanker ship to reach today’s level of improvement. He credited government and public health agencies with providing clear guidelines that businesses, schools and individuals largely followed, including mask mandates and social distancing.

Gov. Gavin Newsom has been allowing businesses and schools to reopen by county based on case levels. At different points in the pandemic, he has faced heavy criticism for being too restrictive, and now some worry he is moving too quickly.

All counties have improved enough to move out of the strictest of four tiers, and 38 of the 58 counties — accounting for 87% of the state’s population — now are in the second least-restrictive tier. Newsom said he plans to lift most remaining coronavirus restrictions by June 15.

The pandemic has surged unevenly across the U.S.

Cases were low in California a year ago, compared with New York, where hospitals were overwhelmed last spring. When California was in the throes of a second winter spike in mid-January, Michigan cases were tapering to a low point in February before surging to the highest current infection rate in the U.S.

Kim-Farley said California’s surge had put fear into more people to wear masks, a rule still in place that he said he has helped prevent a resurgence.

“Some states in the United States that lifted mask mandates are suffering the consequences of that with increasing numbers of cases while we are continuing to see decreases,” he said.

California struggled with its vaccine rollout like other states, limiting doses to health workers and elderly who were more at risk of being hospitalized or dying. Doses have increased as cases have tapered, and the high number of infections over the winter also led to a certain level of natural immunity.

Only weeks ago, counties struggled to get doses. The state limited eligibility for the precious vaccine, and stories abounded of cheaters jumping the line to get a shot.

The Vaccine Spotter website that helps book appointments showed a state map Thursday awash in green dots, indicating available appointments. Many were available the same day, and some sites were allowing people to show up without appointments.

Los Angeles County opened up sites in Palmdale and Lancaster to walk-ups. The largest mass vaccination clinic in Napa County saw demand drop from a flood to a trickle just days after California last week expanded vaccine eligibility to everyone 16 and older. It’s also allowing walk-ins.

“We definitely have the capacity,” county spokeswoman Janet Upton said. “But now what we’re lacking is, seemingly, public interest.”

California has about 40 million residents, and a little more than half the 32 million eligible for vaccines have gotten at least one shot.

A combination of concern over reports of rare complications along with misinformation and conspiracy theories and a sense among some that the danger has waned has led to vaccine hesitancy.

Los Angeles County Public Health Director Barbara Ferrer tried to persuade more people to set aside worries about the vaccine, noting that the chance of a serious side effect is the same as dying in a 200-mile road trip that most people would not hesitate to take.

“The risk of having a serious side effect from COVID vaccine is about one in a million,″ she said. “We take these tiny risks every day as we go about our lives because we know what’s on the other side of it is so worthwhile. Similarly, the return to normal that’s on the other side of vaccination is worthwhile.”

With the rollout of the vaccine, mortuaries that had run out of space have returned to normal.

“It’s the difference between night and day,” said Todd Beckley, the general manager of Inglewood Cemetery Mortuary. “There was a time where we had nine deaths a day, and they were all COVID. We haven’t had a COVID death in four days.”

https://apnews.com/article/pandemics-health-government-and-politics-los-angeles-california-89b0ab03053c4d7daa9749225364892d

J&J COVID-19 vaccine expected to be imported to India by July

 Johnson & Johnson's single-shot COVID-19 vaccine is expected to be imported to India for "fill and finish" by June or July, financial daily Mint reported on Friday, citing ANI.

Fill and finish is the final step in the manufacturing process of putting the vaccine into vials or syringes, sealing them and packaging them up for shipping.

India has said it would fast-track emergency approvals for COVID-19 vaccines authorised by Western countries and Japan, paving the way for possible imports of Pfizer, Johnson & Johnson and Moderna shots.

This will exempt companies from carrying out local safety trials for their vaccines.

India recorded the world's highest daily tally of coronavirus cases for a second day in a row on Friday with 332,730 new cases, while daily deaths from COVID-19 also jumped by a record.

"The Johnson & Johnson vaccines are expected to be imported to India by June-July 2021. Johnson & Johnson is working closely with Biological E to facilitate the ongoing tech transfer to India," Renu Swarup, Secretary, Department of Biotechnology, Ministry of Science and Technology, told Reuters partner ANI on Thursday, according to the report.

Pharmaceutical company Biological E Ltd told Reuters in February it was looking to contract-manufacture roughly 600 million doses of Johnson and Johnson's COVID-19 vaccine annually.

https://www.marketscreener.com/quote/stock/MODERNA-INC-47437573/news/Moderna-nbsp-J-J-COVID-19-vaccine-expected-to-be-imported-to-India-by-July-report-33043658/

Bayer Had a Good Start to 2021: CEO

 Bayer AG had a good start to the year, according to a preliminary version of the speech that the company's chief executive will make at the annual general meeting on Tuesday.

"Early indications suggest that we had a successful start to the year," Chief Executive Werner Baumann said. "In the agriculture business, in particular, we see a market environment that gives us an increasingly positive perspective," he added.

The executive also confirmed that Bayer's sales should grow by around 3% this year assuming constant exchange rates, while earnings per share should be slightly below 2020's level.

Mr. Baumann also said that Bayer's goal will be to regain shareholders' trust after a disappointing stock performance last year. Bayer's share price fell from roughly EUR73 at the start of 2020 to around EUR48 at the end of last year.

The company made the speech available on its website Friday and will release first-quarter results on May 12.

https://www.marketscreener.com/quote/stock/BAYER-AG-436063/news/Bayer-Had-a-Good-Start-to-2021-CEO-Says-33046809/

AbbVie Gets Positive EU Opinion on Leukemia Treatment

 AbbVie Inc. said Friday it received a positive opinion from the European Medicines Agency's Committee for Medicinal Products for Human Use regarding its Venclyxto treatment for people with acute myeloid leukemia.

The opinion covers the use of Venclyxto combined with hypomethylating agents to treat adults with newly diagnosed AML who are ineligible for chemotherapy. The body's opinion is a scientific recommendation that will feed into the European Commission's decision on whether to grant the therapy marketing authorization.

The EC is expected to give its final decision on the therapy in the first half of this year, AbbVie said.

AML is the most common type of acute leukemia, with about 160,000 people in the world currently living with the disease, North Chicago, Ill.-based AbbVie said.

https://www.marketscreener.com/quote/stock/ABBVIE-INC-12136589/news/AbbVie-Gets-Positive-EU-Opinion-on-Leukemia-Treatment-33047935/

Bristol Myers Gets Positive CHMP Opinion for Onureg in Acute Myeloid Leukemia

 Bristol Myers Squibb Co. on Friday said the European Medicines Agency's Committee for Medicinal Products for Human Use recommended approval of Onureg as a maintenance therapy in certain patients with acute myeloid leukemia.

The New York biopharmaceutical company said the recommendation covers adults who achieved complete remission or complete remission with incomplete blood count recovery following induction therapy with or without consolidation treatment and who aren't candidates for hematopoietic stem-cell transplantation.

Bristol Myers said Onureg, if approved, would be the first and only once-daily oral frontline maintenance therapy in Europe to show significant overall survival in patients with a broad range of acute myeloid leukemia subtypes in first remission.

The European Commission, which generally follows CHMP's advice, will review the recommendation and is expected to make a final decision within 67 days of receipt, the company said.

https://www.marketscreener.com/quote/stock/BRISTOL-MYERS-SQUIBB-COMP-11877/news/Bristol-Myers-Gets-Positive-CHMP-Opinion-for-Onureg-in-Acute-Myeloid-Leukemia-33047091/

EU Medicines Agency Urges Boost in Manufacturing Capacity for Covid Vaccines

 The European Medicines Agency said Friday that its human medicines committee has adopted recommendations to increase manufacturing capacity and supply of Covid-19 vaccines in the European Union.

The agency said it has approved an increase in batch size and process scale-up at Pfizer Inc.'s manufacturing site in Puurs, Belgium, a move which is expected to have a "significant" impact on the supply of the vaccine it developed with BioNTech SE.

The agency's committee for medicinal products for human use also recommended the approval of a new filling line at Moderna Inc.'s manufacturing site in Rovi, Spain, the EMA said.

https://www.marketscreener.com/quote/stock/MODERNA-INC-47437573/news/EU-Medicines-Agency-Recommends-Boost-in-Manufacturing-Capacity-for-Covid-Vaccines-33048522/

India's Cadila Healthcare starts producing COVID-19 vaccine candidate

 

India's Cadila Healthcare has started producing its potential COVID-19 vaccine for which it will seek emergency use authorisation in May or June, its managing director told Reuters, with an aim to make up to 240 million doses a year.

"We have just started producing doses," Sharvil Patel said in a Microsoft Teams interview on Friday. "But it is not meaningfully large."

https://www.marketscreener.com/quote/stock/ASTRAZENECA-PLC-4000930/news/India-s-Cadila-Healthcare-starts-producing-COVID-19-vaccine-candidate-33048988/